GlassScriptPhysician profile
Shivani Simmons
NPI 1679001408
$2,136.26
in general payments reported to CMS, 2019-2025
30 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $413 · 2023: $204 · 2024: $110 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $250.31 | 2025 | Talvey, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $213.85 | 2022-2025 | |
| Genzyme Corporation | $175.88 | 2022-2025 | |
| Daiichi Sankyo INC. | $150.26 | 2025 | Datroway, Enhertu, Injectafer |
| Btg International INC. | $131.95 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $110.58 | 2024-2025 | Keytruda, Reblozyl, Welireg |
| Csl Behring | $107.51 | 2021-2023 | Idelvion |
| Pfizer INC. | $103.61 | 2023-2025 | |
| Tersera Therapeutics LLC | $83.30 | 2025 | Xermelo |
| Alexion Pharmaceuticals, INC. | $79.73 | 2022-2025 | Ultomiris |
| Genentech USA, INC. | $75.18 | 2025 | Polivy, Itovebi |
| Incyte Corporation | $67.61 | 2025 | Monjuvi, Jakafi |
| Sobi, INC | $67.11 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.80 | 2022 | |
| Pharmacosmos Therapeutics INC. | $58.23 | 2025 | Monoferric |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $51.65 | 2022-2024 | |
| Pharmaessentia USA Corporation | $50.45 | 2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $36.67 | 2021-2025 | |
| Global Blood Therapeutics, INC. | $36.61 | 2021 | |
| Stemline Therapeutics INC. | $33.67 | 2022-2025 | Orserdu |
| Uswm, LLC | $22.40 | 2024 | Iwilfin |
| Genetix Biotherapeutics INC | $21.48 | 2023 | |
| Beone Medicines USA, INC. | $20.23 | 2025 | Brukinsa |
| Abbvie INC. | $19.77 | 2025 | |
| Exelixis INC. | $19.74 | 2025 | Cabometyx |
| Glaxosmithkline, LLC. | $19.55 | 2025 | Ojjaara |
| Lilly USA, LLC | $18.32 | 2025 | Retevmo, Verzenio, Jaypirca |
| Seagen INC. | $15.29 | 2023 | Adcetris |
| Servier Pharmaceuticals LLC | $14.84 | 2021 | |
| Karyopharm Therapeutics INC. | $14.68 | 2025 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.